Special purpose acquisition companies, known as Spacs or “blank check companies”, are not new but have recently rocketed in popularity as a vehicle for going public faster.
According to Spacinsider, 36 SPACs floated in 2020 with a disclosed interest in the healthcare sector. A further 11 launched in January 2021 alone, with an uptick in the amounts being raised.
Now, signs are emerging that investors are cooling on the opportunity. While there are many factors at play, this could be attributable to increasing SEC scrutiny and a mixed performance from biopharma groups that listed via a Spac.
In this article pack, produced by our team of award-winning journalists, we delve into the world of Spacs – providing insights and data-driven analysis for a deeper understanding of this financing trend and its impact on biotech and medtech.